Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments.
Müller S, Zeidler C, Ständer S.
Am J Clin Dermatol. 2024 Jan;25(1):15-33. doi: 10.1007/s40257-023-00818-z. Epub 2023 Sep 17.
Prurigo nodularis: Pathogenesis and management.
Williams KA, Huang AH, Belzberg M, Kwatra SG.
J Am Acad Dermatol. 2020 Dec;83(6):1567-1575. doi: 10.1016/j.jaad.2020.04.182. Epub 2020 May 24.
Prurigo nodularis: Epidemiology and clinical features.
Huang AH, Williams KA, Kwatra SG.
J Am Acad Dermatol. 2020 Dec;83(6):1559-1565. doi: 10.1016/j.jaad.2020.04.183. Epub 2020 May 23.
[Prurigo nodularis].
Misery L.
Rev Prat. 2020 Feb;70(2):187-189.
Prurigo Nodularis Mechanisms and Current Management Options.
Brown TA, Khachemoune A.
Cutis. 2024 Aug;114(2):E43-E52. doi: 10.12788/cutis.1085.
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Lynde C, De Bruin-Weller MS, Nahm WK, Sauder M, Gharib R, Barbarot S, Szepietowski JC, Conrad C, Fleischer A, Laquer VT, Misery L, Serra-Baldrich E, Lapeere H, Ahmad F, Jabbar Lopez ZK, Piketty C, Ständer S; OLYMPIA 2 Investigators.
N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333.
Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics.
Yook HJ, Lee JH.
Int J Mol Sci. 2024 May 9;25(10):5164. doi: 10.3390/ijms25105164.
Prurigo nodularis: new insights into pathogenesis and novel therapeutics.
Liao V, Cornman HL, Ma E, Kwatra SG.
Br J Dermatol. 2024 May 17;190(6):798-810. doi: 10.1093/bjd/ljae052.
Prurigo Nodularis: Moving Forward.
Hanly A, Watsky KL.
Cutis. 2023 Dec;112(6):262-263. doi: 10.12788/cutis.0903.
Prurigo Nodularis: Review and Emerging Treatments.
Leis M, Fleming P, Lynde CW.
Skin Therapy Lett. 2021 May;26(3):5-8.
